KDM1A and major depressive disorder: TCP is not an ideal therapeutic agent because it lacks specificity for LSD1; it was originally approved by the United States Food and Drug Administration (FDA) for the treatment of depression based on its ability to inhibit monoamine oxidase (MAO).